Format
Sort by

Send to:

Choose Destination

Results: 4

1.

Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.

Winner PK, Sadowsky CH, Martinez WC, Zuniga JA, Poulette A.

Headache. 2012 Sep;52(8):1219-25. doi: 10.1111/j.1526-4610.2012.02164.x. Epub 2012 May 18.

PMID:
22607530
2.

A phase II trial of huperzine A in mild to moderate Alzheimer disease.

Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Thomas R, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2011 Apr 19;76(16):1389-94. doi: 10.1212/WNL.0b013e318216eb7b.

3.

Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.

Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML; MK-677 Protocol 30 Study Group.

Neurology. 2008 Nov 18;71(21):1702-8. doi: 10.1212/01.wnl.0000335163.88054.e7.

PMID:
19015485
4.

High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.

Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ; Alzheimer Disease Cooperative Study.

JAMA. 2008 Oct 15;300(15):1774-83. doi: 10.1001/jama.300.15.1774.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk